Skip to main content
PMC home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1998 Nov 17;159(10):1245–1252.

Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis

E Trindade 1, D Menon 1, L A Topfer 1, C Coloma 1
PMCID: PMC1229819  PMID: 9861221

Abstract

BACKGROUND: The use of antidepressant medications and the resulting costs have increased dramatically in recent years, partly because of the introduction of selective serotonin reuptake inhibitors (SSRIs). An assessment of the clinical and economic aspects of SSRIs compared with the older tricyclic antidepressants (TCAs) was initiated to generate information for purchasers of these drugs as well as clinicians. One component of this study was an examination of the adverse effects associated with the use of these drugs. METHODS: Searches of bibliographic databases (for January 1980 through May 1996) and manual scanning of both peer-reviewed publications and other documents were used to identify double-blind, randomized controlled trials involving at least one SSRI and one TCA. For the study of adverse effects, only trials that had at least 20 patients in each trial arm and that reported rates of adverse effects in both arms were retained. In total 84 trials reporting on 18 adverse effects were available. Meta-analyses were undertaken to calculate pooled differences in rates of adverse effects. The question of whether the method of eliciting information from patients about adverse effects made a difference in the findings was also examined. Finally, differences in drop-out rates due to adverse effects were calculated. RESULTS: The crude rates of occurrence of adverse effects ranged from 4% (palpitations) to 26% (nausea) for SSRIs and from 4% (diarrhea) to 27% (dry mouth) for TCAs. The differences in the rates of adverse effects between the 2 types of drugs ranged from 14% more with SSRIs (for nausea) to 11% more with TCAs (for constipation). The results did not depend on the method of eliciting information from patients. There were no statistically significant differences between drug classes in terms of drop-outs due to adverse effects. INTERPRETATION: SSRIs and TCAs are both associated with adverse effects, although the key effects differ between the drug classes. Further explanation of the adverse effects and their relation to discontinuation of medication will require better studies involving prospective collection of quality-of-life data.

Full Text

The Full Text of this article is available as a PDF (197.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altamura A. C., De Novellis F., Guercetti G., Invernizzi G., Percudani M., Montgomery S. A. Fluoxetine compared with amitriptyline in elderly depression: a controlled clinical trial. Int J Clin Pharmacol Res. 1989;9(6):391–396. [PubMed] [Google Scholar]
  2. Arminen S. L., Ikonen U., Pulkkinen P., Leinonen E., Mahlanen A., Koponen H., Kourula K., Ryyppö J., Korpela V., Lehtonen M. L. A 12-week double-blind multi-centre study of paroxetine and imipramine in hospitalized depressed patients. Acta Psychiatr Scand. 1994 Jun;89(6):382–389. doi: 10.1111/j.1600-0447.1994.tb01533.x. [DOI] [PubMed] [Google Scholar]
  3. Bascara L. A double-blind study to compare the effectiveness and tolerability of paroxetine and amitriptyline in depressed patients. Acta Psychiatr Scand Suppl. 1989;350:141–142. doi: 10.1111/j.1600-0447.1989.tb07196.x. [DOI] [PubMed] [Google Scholar]
  4. Battegay R., Hager M., Rauchfleisch U. Double-blind comparative study of paroxetine and amitriptyline in depressed patients of a university psychiatric outpatient clinic (pilot study). Neuropsychobiology. 1985;13(1-2):31–37. doi: 10.1159/000118159. [DOI] [PubMed] [Google Scholar]
  5. Beasley C. M., Jr, Holman S. L., Potvin J. H. Fluoxetine compared with imipramine in the treatment of inpatient depression. A multicenter trial. Ann Clin Psychiatry. 1993 Sep;5(3):199–207. doi: 10.3109/10401239309148983. [DOI] [PubMed] [Google Scholar]
  6. Beasley C. M., Jr, Sayler M. E., Bosomworth J. C., Wernicke J. F. High-dose fluoxetine: efficacy and activating-sedating effects in agitated and retarded depression. J Clin Psychopharmacol. 1991 Jun;11(3):166–174. [PubMed] [Google Scholar]
  7. Beasley C. M., Jr, Sayler M. E., Potvin J. H. Fluoxetine versus amitriptyline in the treatment of major depression: a multicenter trial. Int Clin Psychopharmacol. 1993 Fall;8(3):143–149. doi: 10.1097/00004850-199300830-00002. [DOI] [PubMed] [Google Scholar]
  8. Bignamini A., Rapisarda V. A double-blind multicentre study of paroxetine and amitriptyline in depressed outpatients. Italian Paroxetine Study Group. Int Clin Psychopharmacol. 1992 Jun;6 (Suppl 4):37–41. doi: 10.1097/00004850-199206004-00008. [DOI] [PubMed] [Google Scholar]
  9. Bowden C. L., Schatzberg A. F., Rosenbaum A., Contreras S. A., Samson J. A., Dessain E., Sayler M. Fluoxetine and desipramine in major depressive disorder. J Clin Psychopharmacol. 1993 Oct;13(5):305–311. [PubMed] [Google Scholar]
  10. Bremner J. D. Fluoxetine in depressed patients: a comparison with imipramine. J Clin Psychiatry. 1984 Oct;45(10):414–419. [PubMed] [Google Scholar]
  11. Byerley W. F., Reimherr F. W., Wood D. R., Grosser B. I. Fluoxetine, a selective serotonin uptake inhibitor, for the treatment of outpatients with major depression. J Clin Psychopharmacol. 1988 Apr;8(2):112–115. [PubMed] [Google Scholar]
  12. Byrne M. M. Meta-analysis of early phase II studies with paroxetine in hospitalized depressed patients. Acta Psychiatr Scand Suppl. 1989;350:138–139. doi: 10.1111/j.1600-0447.1989.tb07194.x. [DOI] [PubMed] [Google Scholar]
  13. Chouinard G. A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. J Clin Psychiatry. 1985 Mar;46(3 Pt 2):32–37. [PubMed] [Google Scholar]
  14. Claghorn J. L., Earl C. Q., Walczak D. D., Stoner K. A., Wong L. F., Kanter D., Houser V. P. Fluvoxamine maleate in the treatment of depression: a single-center, double-blind, placebo-controlled comparison with imipramine in outpatients. J Clin Psychopharmacol. 1996 Apr;16(2):113–120. doi: 10.1097/00004714-199604000-00003. [DOI] [PubMed] [Google Scholar]
  15. Cohn C. K., Shrivastava R., Mendels J., Cohn J. B., Fabre L. F., Claghorn J. L., Dessain E. C., Itil T. M., Lautin A. Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. J Clin Psychiatry. 1990 Dec;51 (Suppl B):28–33. [PubMed] [Google Scholar]
  16. Cohn J. B., Collins G., Ashbrook E., Wernicke J. F. A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol. 1989 Oct;4(4):313–322. doi: 10.1097/00004850-198910000-00006. [DOI] [PubMed] [Google Scholar]
  17. Cohn J. B., Wilcox C. S. Paroxetine in major depression: a double-blind trial with imipramine and placebo. J Clin Psychiatry. 1992 Feb;53 (Suppl):52–56. [PubMed] [Google Scholar]
  18. Cohn J. B., Wilcox C. A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder. J Clin Psychiatry. 1985 Mar;46(3 Pt 2):26–31. [PubMed] [Google Scholar]
  19. Coleman B. S., Block B. A. Fluvoxamine maleate, a serotonergic antidepressant; a comparison with chlorimipramine. Prog Neuropsychopharmacol Biol Psychiatry. 1982;6(4-6):475–478. doi: 10.1016/s0278-5846(82)80132-2. [DOI] [PubMed] [Google Scholar]
  20. Dominguez R. A., Goldstein B. J., Jacobson A. F., Steinbook R. M. A double-blind placebo-controlled study of fluvoxamine and imipramine in depression. J Clin Psychiatry. 1985 Mar;46(3):84–87. [PubMed] [Google Scholar]
  21. Doogan D. P., Langdon C. J. A double-blind, placebo-controlled comparison of sertraline and dothiepin in the treatment of major depression in general practice. Int Clin Psychopharmacol. 1994 Summer;9(2):95–100. doi: 10.1097/00004850-199400920-00005. [DOI] [PubMed] [Google Scholar]
  22. Dunbar G. C., Cohn J. B., Fabre L. F., Feighner J. P., Fieve R. R., Mendels J., Shrivastava R. K. A comparison of paroxetine, imipramine and placebo in depressed out-patients. Br J Psychiatry. 1991 Sep;159:394–398. doi: 10.1192/bjp.159.3.394. [DOI] [PubMed] [Google Scholar]
  23. Dunner D. L., Cohn J. B., Walshe T., 3rd, Cohn C. K., Feighner J. P., Fieve R. R., Halikas J. P., Hartford J. T., Hearst E. D., Settle E. C., Jr Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression. J Clin Psychiatry. 1992 Feb;53 (Suppl):57–60. [PubMed] [Google Scholar]
  24. Fabre L. F. A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients. J Clin Psychiatry. 1992 Feb;53 (Suppl):40–43. [PubMed] [Google Scholar]
  25. Fabre L. F., Scharf M. B., Itil T. M. Comparative efficacy and safety of nortriptyline and fluoxetine in the treatment of major depression: a clinical study. J Clin Psychiatry. 1991 Jun;52 (Suppl):62–67. [PubMed] [Google Scholar]
  26. Fabre L., Birkhimer L. J., Zaborny B. A., Wong L. F., Kapik B. M. Fluvoxamine versus imipramine and placebo: a double-blind comparison in depressed patients. Int Clin Psychopharmacol. 1996 Jun;11(2):119–127. [PubMed] [Google Scholar]
  27. Feighner J. P. A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder. J Clin Psychiatry. 1985 Sep;46(9):369–372. [PubMed] [Google Scholar]
  28. Feighner J. P., Boyer W. F., Meredith C. H., Hendrickson G. G. A placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression. Int Clin Psychopharmacol. 1989 Jul;4(3):239–244. doi: 10.1097/00004850-198907000-00006. [DOI] [PubMed] [Google Scholar]
  29. Feighner J. P., Boyer W. F., Merideth C. H., Hendrickson G. G. A double-blind comparison of fluoxetine, imipramine and placebo in outpatients with major depression. Int Clin Psychopharmacol. 1989 Apr;4(2):127–134. doi: 10.1097/00004850-198904000-00004. [DOI] [PubMed] [Google Scholar]
  30. Feighner J. P., Boyer W. F. Paroxetine in the treatment of depression: a comparison with imipramine and placebo. Acta Psychiatr Scand Suppl. 1989;350:125–129. doi: 10.1111/j.1600-0447.1989.tb07190.x. [DOI] [PubMed] [Google Scholar]
  31. Feighner J. P., Cohn J. B. Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. J Clin Psychiatry. 1985 Mar;46(3 Pt 2):20–25. [PubMed] [Google Scholar]
  32. Feighner J. P., Cohn J. B., Fabre L. F., Jr, Fieve R. R., Mendels J., Shrivastava R. K., Dunbar G. C. A study comparing paroxetine placebo and imipramine in depressed patients. J Affect Disord. 1993 Jun;28(2):71–79. doi: 10.1016/0165-0327(93)90035-i. [DOI] [PubMed] [Google Scholar]
  33. Freemantle N., House A., Song F., Mason J. M., Sheldon T. A. Prescribing selective serotonin reuptake inhibitors as strategy for prevention of suicide. BMJ. 1994 Jul 23;309(6949):249–253. doi: 10.1136/bmj.309.6949.249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Gasperini M., Gatti F., Bellini L., Anniverno R., Smeraldi E. Perspectives in clinical psychopharmacology of amitriptyline and fluvoxamine. A double-blind study in depressed inpatients. Neuropsychobiology. 1992;26(4):186–192. doi: 10.1159/000118918. [DOI] [PubMed] [Google Scholar]
  35. Geretsegger C., Stuppaeck C. H., Mair M., Platz T., Fartacek R., Heim M. Multicenter double blind study of paroxetine and amitriptyline in elderly depressed inpatients. Psychopharmacology (Berl) 1995 Jun;119(3):277–281. doi: 10.1007/BF02246291. [DOI] [PubMed] [Google Scholar]
  36. Ginestet D. Fluoxetine in endogenous depression and melancholia versus clomipramine. Int Clin Psychopharmacol. 1989 Jan;4 (Suppl 1):37–40. [PubMed] [Google Scholar]
  37. Guelfi J. D., Dreyfus J. F., Pichot P. A double-blind controlled clinical trial comparing fluvoxamine with imipramine. Br J Clin Pharmacol. 1983;15 (Suppl 3):411S–417S. doi: 10.1111/j.1365-2125.1983.tb02131.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Guillibert E., Pelicier Y., Archambault J. C., Chabannes J. P., Clerc G., Desvilles M., Guibert M., Pagot R., Poisat J. L., Thobie Y. A double-blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients. Acta Psychiatr Scand Suppl. 1989;350:132–134. doi: 10.1111/j.1600-0447.1989.tb07192.x. [DOI] [PubMed] [Google Scholar]
  39. Guy W., Wilson W. H., Ban T. A., King D. L., Manov G., Fjetland O. K. A double-blind clinical trial of fluvoxamine and imipramine in patients with primary depression. Psychopharmacol Bull. 1984 Winter;20(1):73–78. [PubMed] [Google Scholar]
  40. Hotopf M., Lewis G., Normand C. Are SSRIs a cost-effective alternative to tricyclics? Br J Psychiatry. 1996 Apr;168(4):404–409. doi: 10.1192/bjp.168.4.404. [DOI] [PubMed] [Google Scholar]
  41. Hutchinson D. R., Tong S., Moon C. A., Vince M., Clarke A. Paroxetine in the treatment of elderly depressed patients in general practice: a double-blind comparison with amitriptyline. Int Clin Psychopharmacol. 1992 Jun;6 (Suppl 4):43–51. doi: 10.1097/00004850-199206004-00009. [DOI] [PubMed] [Google Scholar]
  42. Itil T. M., Shrivastava R. K., Mukherjee S., Coleman B. S., Michael S. T. A double-blind placebo-controlled study of fluvoxamine and imipramine in out-patients with primary depression. Br J Clin Pharmacol. 1983;15 (Suppl 3):433S–438S. doi: 10.1111/j.1365-2125.1983.tb02134.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Judd F. K., Moore K., Norman T. R., Burrows G. D., Gupta R. K., Parker G. A multicentre double blind trial of fluoxetine versus amitriptyline in the treatment of depressive illness. Aust N Z J Psychiatry. 1993 Mar;27(1):49–55. doi: 10.3109/00048679309072123. [DOI] [PubMed] [Google Scholar]
  44. Keegan D., Bowen R. C., Blackshaw S., Saleh S., Dayal N., Remillard F., Shrikhande S., Cebrian Perez S., Boulton A. A comparison of fluoxetine and amitriptyline in the treatment of major depression. Int Clin Psychopharmacol. 1991 Summer;6(2):117–124. doi: 10.1097/00004850-199100620-00007. [DOI] [PubMed] [Google Scholar]
  45. Kuhs H., Rudolf G. A. A double-blind study of the comparative antidepressant effect of paroxetine and amitriptyline. Acta Psychiatr Scand Suppl. 1989;350:145–146. doi: 10.1111/j.1600-0447.1989.tb07198.x. [DOI] [PubMed] [Google Scholar]
  46. Laakmann G., Blaschke D., Engel R., Schwarz A. Fluoxetine vs amitriptyline in the treatment of depressed out-patients. Br J Psychiatry Suppl. 1988 Sep;(3):64–68. [PubMed] [Google Scholar]
  47. Lapierre Y. D., Browne M., Horn E., Oyewumi L. K., Sarantidis D., Roberts N., Badoe K., Tessier P. Treatment of major affective disorder with fluvoxamine. J Clin Psychiatry. 1987 Feb;48(2):65–68. [PubMed] [Google Scholar]
  48. Laursen A. L., Mikkelsen P. L., Rasmussen S., le Fèvre Honoré P. Paroxetine in the treatment of depression--a randomized comparison with amitriptyline. Acta Psychiatr Scand. 1985 Mar;71(3):249–255. doi: 10.1111/j.1600-0447.1985.tb01281.x. [DOI] [PubMed] [Google Scholar]
  49. Levine S., Deo R., Mahadevan K. A comparative trial of a new antidepressant, fluoxetine. Int Clin Psychopharmacol. 1989 Jan;4 (Suppl 1):41–45. [PubMed] [Google Scholar]
  50. Moon C. A., Vince M. Treatment of major depression in general practice: a double-blind comparison of paroxetine and lofepramine. Br J Clin Pract. 1996 Jul-Aug;50(5):240–244. [PubMed] [Google Scholar]
  51. Mullin J. M., Pandita-Gunawardena V. R., Whitehead A. M. A double-blind comparison of fluvoxamine and dothiepin in the treatment of major affective disorder. Br J Clin Pract. 1988 Feb;42(2):51–55. [PubMed] [Google Scholar]
  52. Möller H. J., Berzewski H., Eckmann F., Gonzalves N., Kissling W., Knorr W., Ressler P., Rudolf G. A., Steinmeyer E. M., Magyar I. Double-blind multicenter study of paroxetine and amitriptyline in depressed inpatients. Pharmacopsychiatry. 1993 May;26(3):75–78. doi: 10.1055/s-2007-1014346. [DOI] [PubMed] [Google Scholar]
  53. Nathan R. S., Perel J. M., Pollock B. G., Kupfer D. J. The role of neuropharmacologic selectivity in antidepressant action: fluvoxamine versus desipramine. J Clin Psychiatry. 1990 Sep;51(9):367–372. [PubMed] [Google Scholar]
  54. Nielsen B. M., Behnke K., Arup P., Christiansen P. E., Geisler A., Ipsen E., Maach-Møller B., Ohrberg S. C. A comparison of fluoxetine and imipramine in the treatment of outpatients with major depressive disorder. Acta Psychiatr Scand. 1993 Apr;87(4):269–272. doi: 10.1111/j.1600-0447.1993.tb03370.x. [DOI] [PubMed] [Google Scholar]
  55. Nielsen O. A., Morsing I., Petersen J. S., Larsen T., Møller S. E., Manniche P. M., Skausig O. B. Paroxetine and imipramine treatment of depressive patients in a controlled multicentre study with plasma amino acid measurements. Acta Psychiatr Scand. 1991 Sep;84(3):233–241. doi: 10.1111/j.1600-0447.1991.tb03136.x. [DOI] [PubMed] [Google Scholar]
  56. Noguera R., Altuna R., Alvarez E., Ayuso J. L., Casais L., Udina C. Fluoxetine vs. clomipramine in depressed patients: a controlled multicentre trial. J Affect Disord. 1991 Jul;22(3):119–124. doi: 10.1016/0165-0327(91)90045-t. [DOI] [PubMed] [Google Scholar]
  57. Nolen W. A., van de Putte J. J., Dijken W. A., Kamp J. S., Blansjaar B. A., Kramer H. J., Haffmans J. Treatment strategy in depression. I. Non-tricyclic and selective reuptake inhibitors in resistant depression: a double-blind partial crossover study on the effects of oxaprotiline and fluvoxamine. Acta Psychiatr Scand. 1988 Dec;78(6):668–675. doi: 10.1111/j.1600-0447.1988.tb06402.x. [DOI] [PubMed] [Google Scholar]
  58. Norton K. R., Sireling L. I., Bhat A. V., Rao B., Paykel E. S. A double-blind comparison of fluvoxamine, imipramine and placebo in depressed patients. J Affect Disord. 1984 Dec;7(3-4):297–308. doi: 10.1016/0165-0327(84)90051-x. [DOI] [PubMed] [Google Scholar]
  59. Ohrberg S., Christiansen P. E., Severin B., Calberg H., Nilakantan B., Borup A., Søgaard J., Larsen S. B., Loldrup D., Bahr B. Paroxetine and imipramine in the treatment of depressive patients in psychiatric practice. Acta Psychiatr Scand. 1992 Dec;86(6):437–444. doi: 10.1111/j.1600-0447.1992.tb03294.x. [DOI] [PubMed] [Google Scholar]
  60. Peselow E. D., Filippi A. M., Goodnick P., Barouche F., Fieve R. R. The short- and long-term efficacy of paroxetine HCl: A. Data from a 6-week double-blind parallel design trial vs. imipramine and placebo. Psychopharmacol Bull. 1989;25(2):267–271. [PubMed] [Google Scholar]
  61. Poelinger W., Haber H. Fluoxetine 40 mg vs maprotiline 75 mg in the treatment of out-patients with depressive disorders. Int Clin Psychopharmacol. 1989 Jan;4 (Suppl 1):47–50. [PubMed] [Google Scholar]
  62. Pélicier Y., Schaeffer P. Etude multicentrique en double aveugle comparant l'efficacité et la tolérance de la paroxétine et de la clomipramine dans la dépression réactionnelle du sujet âgé. Encephale. 1993 May-Jun;19(3):257–261. [PubMed] [Google Scholar]
  63. Reimherr F. W., Byerley W. F., Ward M. F., Lebegue B. J., Wender P. H. Sertraline, a selective inhibitor of serotonin uptake, for the treatment of outpatients with major depressive disorder. Psychopharmacol Bull. 1988;24(1):200–205. [PubMed] [Google Scholar]
  64. Reimherr F. W., Chouinard G., Cohn C. K., Cole J. O., Itil T. M., LaPierre Y. D., Masco H. L., Mendels J. Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry. 1990 Dec;51 (Suppl B):18–27. [PubMed] [Google Scholar]
  65. Revicki D. A., Brown R. E., Keller M. B., Gonzales J., Culpepper L., Hales R. E. Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings. J Clin Psychiatry. 1997 Feb;58(2):47–58. doi: 10.4088/jcp.v58n0201. [DOI] [PubMed] [Google Scholar]
  66. Ropert R. Fluoxetine versus clomipramine in major depressive disorders. Int Clin Psychopharmacol. 1989 Jan;4 (Suppl 1):89–95. [PubMed] [Google Scholar]
  67. Shrivastava R. K., Shrivastava S. H., Overweg N., Blumhardt C. L. A double-blind comparison of paroxetine, imipramine, and placebo in major depression. J Clin Psychiatry. 1992 Feb;53 (Suppl):48–51. [PubMed] [Google Scholar]
  68. Staner L., Kerkhofs M., Detroux D., Leyman S., Linkowski P., Mendlewicz J. Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxetine and amitriptyline: a double-blind randomized trial in major depression. Sleep. 1995 Jul;18(6):470–477. [PubMed] [Google Scholar]
  69. Stark P., Hardison C. D. A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder. J Clin Psychiatry. 1985 Mar;46(3 Pt 2):53–58. [PubMed] [Google Scholar]
  70. Tamminen T. T., Lehtinen V. V. A double-blind parallel study to compare fluoxetine with doxepin in the treatment of major depressive disorders. Int Clin Psychopharmacol. 1989 Jan;4 (Suppl 1):51–56. [PubMed] [Google Scholar]
  71. Teicher M. H., Glod C. A., Cole J. O. Antidepressant drugs and the emergence of suicidal tendencies. Drug Saf. 1993 Mar;8(3):186–212. doi: 10.2165/00002018-199308030-00002. [DOI] [PubMed] [Google Scholar]
  72. Young J. P., Coleman A., Lader M. H. A controlled comparison of fluoxetine and amitriptyline in depressed out-patients. Br J Psychiatry. 1987 Sep;151:337–340. doi: 10.1192/bjp.151.3.337. [DOI] [PubMed] [Google Scholar]
  73. de Jonghe F., Ravelli D. P., Tuynman-Qua H. A randomized, double-blind study of fluoxetine and maprotiline in the treatment of major depression. Pharmacopsychiatry. 1991 Mar;24(2):62–67. doi: 10.1055/s-2007-1014440. [DOI] [PubMed] [Google Scholar]
  74. de Jonghe F., Swinkels J., Tuynman-Qua H. Randomized double-blind study of fluvoxamine and maprotiline in treatment of depression. Pharmacopsychiatry. 1991 Jan;24(1):21–27. doi: 10.1055/s-2007-1014428. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES